ArticleBiomaterials2014
Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 63 citations in OpenAlex.
- Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions.International journal of molecular sciences · 2026Review
- Molecular design of MRI probes for targeting amyloid-β species: fromTheranostics · 2026Review
- Nanoscale drug formulations for the treatment of Alzheimer's disease progression.RSC advances · 2025Review
- A Promising Approach: Magnetic Nanosystems for Alzheimer's Disease Theranostics.Pharmaceutics · 2023Review
- Deconvolution of Plasma Pharmacokinetics from Dynamic Heart Imaging Data Obtained by Single Positron Emission Computed Tomography/Computed Tomography Imaging.The Journal of pharmacology and experimental therapeutics · 2023Article
- Development of a PET radioligand selective for cerebral amyloid angiopathy.Nuclear medicine and biology · 2021Article
- Natural Polysaccharide Carriers in Brain Delivery: Challenge and Perspective.Pharmaceutics · 2020Review
- Curcumin Formulations and Trials: What's New in Neurological Diseases.Molecules (Basel, Switzerland) · 2020Review
- Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations.Molecules (Basel, Switzerland) · 2020Review
- High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-The Journal of pharmacology and experimental therapeutics · 2020Article
- Curcumin's Nanomedicine Formulations for Therapeutic Application in Neurological Diseases.Journal of clinical medicine · 2020Review
- Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs.Frontiers in neuroscience · 2020Review
- Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019Review
- Personalized nanomedicine for CNS diseases.Drug discovery today · 2018Review
- Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Article
- Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.Current Alzheimer research · 2017Review
- Nano-biosensors to detect beta-amyloid for Alzheimer's disease management.Biosensors & bioelectronics · 2016Review
- Imaging of Cerebral Amyloid Angiopathy with Bivalent (99m)Tc-Hydroxamamide Complexes.Scientific reports · 2016Article
- Therapeutic Applications of Curcumin Nanoformulations.The AAPS journal · 2015Review
- Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Cerebral amyloid angiopathy (CAA) results from the accumulation of Aβ proteins primarily within the media and adventitia of small arteries and capillaries of the cortex and leptomeninges. CAA affects a majority of Alzheimer's disease (AD) patients and is associated with a rapid decline in cognitive reserve. Unfortunately, there is no pre-mortem diagnosis available for CAA. Furthermore, treatment options are few and relatively ineffective. To combat this issue, we have designed nanovehicles (nanoparticles-IgG4.1) capable of targeting cerebrovascular amyloid (CVA) and serving as early diagnostic and therapeutic agents. These nanovehicles were loaded with Gadolinium (Gd) based (Magnevist(®)) magnetic resonance imaging contrast agents or single photon emission computed tomography (SPECT) agents, such as (125)I. In addition, the nanovehicles carry either anti-inflammatory and anti-amyloidogenic agents such as curcumin or immunosuppressants such as dexamethasone, which were previously shown to reduce cerebrovascular inflammation. Owing to the anti-amyloid antibody (IgG4.1) grafted on the surface, the nanovehicles are capable of specifically targeting CVA deposits. The nanovehicles effectively marginate from the blood flow to the vascular wall as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. They demonstrate excellent distribution to the brain vasculature and target CVA, thus providing MRI and SPECT contrast specific to the CVA in the brain. In addition, they also display the potential to carry therapeutic agents to reduce cerebrovascular inflammation associated with CAA, which is believed to trigger hemorrhage in CAA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.